Hemic and Lymphatic Diseases

607 trials 239 recruiting

Filter these 607 trials by phase, country and sponsor.

Open in Search →

A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in People With Hemophilia A Recruiting

2025-522434-32-00 Hemophilia A Without Inhibitors 5 2026-07-01
A study testing the new drug Lisaftoclax for newly diagnosed acute myeloid leukemia(GLORA-3) Recruiting

2024-516436-10-00 Acute myeloid leukemia 5 2026-06-18
A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People with Hemophilia A Recruiting

2025-522435-33-00 Hemophilia A 5 2026-06-17
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma Recruiting

2023-505200-33-00 Multiple myeloma 5 2026-06-15
A Global Study Testing the New Drug Olverembatinib combined with chemotherapy for Patients with Newly Diagnosed Philadelphia Chromosome-Pos… Recruiting

2024-511496-14-00 Newly Diagnosed Philadelphia Chromosome-Positive Acute 5 2026-05-14
Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults with Hemophilia B with Pretreatment Adeno-associated Virus … Recruiting

2023-509590-23-00 Hemophilia B 5 2026-04-22
A study to investigate the efficacy and safety of fitusiran prophylaxis in male participants aged 1 to less than 12 years with hemophilia A … Recruiting

2025-521858-42-00 Hemophilia 5 2026-03-16
morPHinE clearance and glomerular filtration in the Drepanocytic in crisis in REAnimation. Recruiting

2024-511985-34-00 Evaluation of the CKD-Epi score to identify a glomerula 6 2026-03-05
A Phase 1 Study of AJ1-11095 in Adults with Myelofibrosis Failed by a JAK2 Inhibitor Recruiting

2025-522033-64-00 Myelofibrosis 1 2026-02-26
LUSPARA - Luspatercept in patients affected with rare inherited anemias Recruiting

2024-520200-26-00 Inherited anemias 4 2026-02-13
Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL. Recruiting

2025-522052-13-00 Framework for Optimizing, Refining, and Unifying Manage 10 2025-12-24
A Phase 3 Study of DZD8586 versus Investigator’s Choice in r/r CLL/SLL Recruiting

2025-522669-32-00 Relapsed/Refractory Chronic Lymphocytic Leukemia/Small 5 2025-12-18
Study on chemotherapy and experimental drugs in patients with Philadelphia Chromosome positive and ABL-class Philadelphia Chromosome-Like B-… Recruiting

2025-520982-39-00 Philadelphia Chromosome Positive or ABL-class Philadelp 5 2025-12-09
EAST-1 (ERAP-inhibition in Axial Spondyloarthritis Trial-1) Recruiting

2025-521315-39-00 Axial spondyloarthritis 1 2025-11-05
The efficacy and safety of rilzabrutinib in participants aged 10 to 65 years with sickle-cell disease Recruiting

2024-518645-17-00 Blood and lymphatic diseases 5 2025-10-07
Clinical study of ruxolitinib and venetoclax for children with relapsed or refractory leukemia or lymphoma with mutations in the IL-7R/JAK-S… Recruiting

2022-501867-42-01 Acute Lymphoblastic Leukemia, in Relapse Lymphoblastic 9 2025-09-08
Medical-scientific study of dasatinib and venetoclax for children with relapsed or refractory leukemia or lymphoma with a mutation in the MA… Recruiting

2022-501866-22-00 Acute Lymphoblastic Leukemia, in Relapse Lymphoblastic 9 2025-08-26
A Worldwide Study Testing the New Drug Lisaftoclax for Patients with Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma… Recruiting

2024-514084-26-00 Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymp 5 2025-08-22
A Phase 1/2a, First-in-human Study to Evaluate BMS-986470 in Healthy Volunteers and Participants with Sickle Cell Disease Recruiting

2023-510283-12-00 Sickle Cell Disease 7 2025-06-12
A Study to assess safety and effectiveness of Emicizumab in Patients with Type 3 Von Willebrand Disease Recruiting

2024-515622-80-00 Type 3 Von Willebrand Disease 5 2025-06-04
Long-term Follow-up study for relapsed/refractory (R/R) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LL) patients previously treated … Recruiting

2024-516617-20-00 T-cell acute lymphoblastic Lymphoma 5 2025-05-21
A Phase 1, dose determining study of EXS73565 in participants with relapsed or refractory B‑cell malignancies. Recruiting

2024-516869-36-00 Relapsed or refractory B-cell malignancies: chronic lym 1 2025-02-17
A Phase Ib Safety, Pharmacokinetics and Pharmacodynamics Study of TU7710 in Patients with Haemophilia A or B Recruiting

2024-511814-20-00 Hemophilia 3 2024-12-10
A preventive study of bleeding episodes for children with severe von Willebrand disease (VWD). Recruiting

2023-509877-22-00 severe von Willebrand Disease 5 2024-10-30